NewAmsterdam Q3 Revenue Jumps to $19.2M; PREVAIL Interim Result Due 1Q2027
NAMS is trading near its 52-week low of $19.13 (8.2% above the low).
Summary
NewAmsterdam reported Q3 revenue of $19.2M (vs $0.3M a year ago) and a narrowed $17.4M net loss, with $643.1M in cash. The PREVAIL cardiovascular outcomes interim result is expected in 1Q2027 and RUBENS topline around year-end 2026.
Key Events · Earnings and Guidance · NAMS
-
Q3 Revenue Jumps on Menarini Milestones
Revenue was $19.2M for the quarter ended September 30, 2026, versus $0.3M a year earlier, primarily from recognition of regulatory milestones under the Menarini license.
-
Net Loss Narrows on Non-Cash Warrant Gain
Net loss fell to $17.4M from $72.0M, including a $23.1M non-cash fair-value gain on derivative warrant liabilities — a mark-to-market entry, not cash or new dilution.
-
Cash of $643.1M Funds Readouts
Cash, cash equivalents and marketable securities totaled $643.1M at September 30, 2026, down from $728.9M at December 31, 2025, with $109.6M used in operations over nine months.
-
PREVAIL Interim Result Expected 1Q2027
The company expects to reach the predefined event number for the PREVAIL interim analysis in 4Q2026, with the result expected in 1Q2027; RUBENS Phase 3 topline is expected around year-end 2026.
Analysis · NAMS · Life Sciences
This is the first top-line print since European approval of obicetrapib, and the headline revenue of $19.2M versus $0.3M a year ago mostly reflects Menarini milestone recognition rather than product sales. The net loss narrowed to $17.4M from $72.0M, largely on a $23.1M non-cash warrant remeasurement gain — an accounting mark, not cash. What matters more is the calendar: PREVAIL, the first CETP outcomes trial in over a decade, hits its event target in 4Q2026 with the result expected 1Q2027, and RUBENS topline lands around year-end 2026. With $643.1M in cash, the company is funded into those readouts, so the binary risk is clinical, not financial.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NAMS was trading at $20.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $19.13 to $42.21. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.